Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
Colorectal Cancer
DRUG: S-1, Irinotecan, Bevacizumab
Safety, any time
Progression-free survival, Response rate, Overall survival, Treatment situation, every course for first three courses, then every other course
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer